Olodaterol: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Olodaterol

Selective Beta-2-Adrenoreceptor Agonists

GB MHRA

Drug class: Selective Beta-2-Adrenoreceptor Agonists
Availability: See label
Markets covered: 1
Products on record: 3

R03ACSelective Beta-2-Adrenoreceptor Agonists

Overview

Olodaterol is an active pharmaceutical ingredient in the Selective Beta-2-Adrenoreceptor Agonists group (R03AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	3	May 15, 2026

GBUnited Kingdom· MHRA

3 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

Striverdi Respimat is indicated as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD).

How to take

Drug interactions

Known interactions involving Olodaterol. Select one for details. This list is informational and not a complete interaction checker.

Carteolol Carvedilol Cocaine Labetalol Levobunolol Macimorelin Metipranolol Nadolol Ozanimod Penbutolol Pindolol Propranolol Ribociclib Sotalol Timolol Abarelix Abiraterone Acebutolol Acetazolamide Albiglutide Albuterol Alfuzosin Aminophylline Amiodarone Amisulpride Amitriptyline Amoxapine Amphetamine Anagrelide Apalutamide Apomorphine Arformoterol Aripiprazole Armodafinil Arsenic Trioxide Asenapine Astemizole Atenolol Atomoxetine Azithromycin Bedaquiline Bendroflumethiazide Benzphetamine Benzthiazide Bepridil Betaxolol Bicalutamide Bisoprolol Bosutinib Bumetanide Buprenorphine Cabozantinib Canagliflozin Ceritinib Chloroquine Chlorothiazide Chlorpromazine Chlorthalidone Cilostazol Ciprofloxacin Cisapride Citalopram Clarithromycin Clofazimine Clomipramine Clozapine Crizotinib Dasatinib Daunorubicin Degarelix Desipramine Desvenlafaxine Deutetrabenazine Dexmethylphenidate Dextroamphetamine Diethylpropion Dipivefrin Disopyramide Dobutamine Dofetilide Dolasetron Donepezil Dopamine Doxapram Doxepin Doxorubicin Dronedarone Droperidol Duloxetine Dyphylline Efavirenz Encorafenib Entrectinib Enzalutamide Ephedrine Epinephrine Epirubicin Eribulin Ertugliflozin Erythromycin Escitalopram Esmolol Ethacrynate Ezogabine Famotidine Fenfluramine Fingolimod Flecainide Fluconazole Fluoxetine Fluphenazine Flutamide Formoterol Foscarnet Fostemsavir Furosemide Galantamine Gatifloxacin Gemifloxacin Gilteritinib Glasdegib Goserelin Granisetron Grepafloxacin Halofantrine Haloperidol Halothane Histrelin Hydrochlorothiazide Hydroflumethiazide Hydroxychloroquine Hydroxyzine Ibutilide Idarubicin Iloperidone Imipramine Indacaterol Indapamide Inotuzumab Ozogamicin Isocarboxazid Isoetharine Isometheptene Isoproterenol Ivabradine Ivosidenib Ketamine Ketoconazole Lapatinib Lefamulin Lenvatinib Leuprolide Levofloxacin Levomilnacipran Levonordefrin Linezolid Lisdexamfetamine Lithium Carbonate Lixisenatide Lofexidine Lomefloxacin Loperamide Lopinavir Lumefantrine Mannitol Maprotiline Mazindol Mefloquine Mephentermine Mesoridazine Metaproterenol Metaraminol Methadone Methazolamide Methotrimeprazine Methoxamine Methylene Blue Methylphenidate Metolazone Metoprolol Midodrine Midostaurin Mifepristone Milnacipran Mirtazapine Modafinil Moxifloxacin Naphazoline Nebivolol Nilotinib Nilutamide Norepinephrine Norfloxacin Nortriptyline Ofloxacin Olanzapine Oliceridine Ondansetron Osilodrostat Osimertinib Oxaliplatin Oxtriphylline Oxymetazoline Oxytocin Paliperidone Palonosetron Panobinostat Pasireotide Pazopanib Pentamidine Perflutren Perphenazine Phendimetrazine Phenelzine Phentermine Phenylephrine Phenylpropanolamine Pimavanserin Pimozide Pirbuterol Pitolisant Polythiazide Posaconazole Primaquine Probucol Procainamide Procarbazine Prochlorperazine Promazine Promethazine Propafenone Propofol Propoxyphene Propylhexedrine Protriptyline Pseudoephedrine Quetiapine Quinidine Quinine Racepinephrine Ranolazine

Showing 240 of 298. Type above to find a specific drug.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL145980093 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Posology The medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat inhaler. Two actuations (puffs) from the Respimat inhaler comprise one medicinal dose. Adults The recommended dose is 5 microgram olodaterol given as two actuations (puffs) from the Respimat inhaler once daily, at the same time of the day.
The recommended dose should not be exceeded. Elderly population Elderly patients can use Striverdi Respimat at the recommended dose. Hepatic impairment Patients with mild and moderate hepatic impairment can use Striverdi Respimat at the recommended dose.
There are no data available for use of Striverdi Respimat in patients with severe hepatic impairment. Renal impairment Renally impaired patients can use Striverdi Respimat at the recommended dose. There is limited experience with the use of Striverdi Respimat in patients with severe renal impairment.
Paediatric population There is no relevant use of Striverdi Respimat in the paediatric population (under 18 years). Method of administration This medicinal product is intended for inhalation use only. The cartridge can only be inserted and used in the Respimat re-usable inhaler.
Respimat is an inhaler device that generates a spray for inhalation. It is meant for use by a single patient and intended for multiple doses delivered by one cartridge. The Respimat re-usable inhaler allows for replacement of the cartridge, and can be used with up to 6 cartridges.
Patients should read the instructions on how to use the Respimat re-usable inhaler before they start using Striverdi Respimat. To ensure proper administration of the medicinal product, the patient should be shown how to use the inhaler by a physician or other health care professional.
Instructions for handling and use of the Respimat re-usable inhaler The patient will need to use this inhaler only ONCE A DAY. Each time used take TWO ACTUATIONS (PUFFS). • If Striverdi Respimat has not been used for more than 7 days release one actuation (puff) towards the ground.
• If Striverdi Respimat has not been used for more than 21 days repeat steps 4 to 6 under ‘Prepare for use’ until a cloud is visible. Then repeat steps 4 to 6 three more times. How to care for the Respimat re-usable inhaler Clean the mouthpiece including the metal part inside the mouthpiece with a damp cloth or tissue only, at least once a week.
Any minor discoloration in the mouthpiece does not affect the Respimat re-usable inhaler performance. If necessary, wipe the outside of the Respimat re-usable inhaler with a damp cloth. When to replace the inhaler When the patient has used an inhaler with 6 cartridges, get a new Striverdi Respimat pack containing an inhaler.
Do not use the Respimat re-usable inhaler for more than one year, after having inserted the first cartridge. Prepare for use 1. Remove clear base • Keep the cap closed. • Press the safety catch while pulling off the clear base with the other hand.
2. Insert cartridge • Insert the cartridge into the inhaler. • Place the inhaler on a firm surface and push down firmly until it clicks into place. 3. Track cartridge and put the clear base back • Mark the check-box on inhaler’s label to track the number of cartridges • Put the clear base back into place until it clicks.
4. Turn • Keep the cap closed. • Turn the clear base in the direction of the arrows on the label until it clicks (half a turn). 5. Open • Open the cap until it snaps fully open. 6. Press • Point the inhaler toward the ground. • Press the dose-release button.
• Close the cap. • Repeat steps 4-6 until a cloud is visible. • After a cloud is visible, repeat steps 4-6 three more times. The inhaler is now ready to use and will deliver 60 actuations (puffs) (30 doses). Daily use TURN • Keep the cap closed.
• TURN the clear base in the direction of the arrows on the label until it clicks (half a turn). OPEN • OPEN the cap until it snaps fully open. PRESS • Breathe out slowly and fully. • Close the lips around the mouthpiece without covering the air vents.
Point the Inhaler to the back of the throat. • While taking a slow, deep breath through the mouth, PRESS the dose- release button and continue to breathe in slowly for as long as comfortable. • Hold the breath for 10 seconds or for as long as comfortable.
• Repeat Turn, Open, Press for a total of 2 actuations (puffs). • Close the cap until the inhaler is used again. When to replace the Striverdi Respimat cartridge The dose indicator shows how many actuations (puffs) remain in the cartridge.
60 actuations (puffs) remaining. Less than 10 actuations (puffs) remaining. Obtain a new cartridge. The cartridge is used up. Turn the clear base to loosen it. The inhaler is now in a locked position. Pull off the cartridge from the inhaler.
Insert a new cartridge until it clicks (refer to step 2). The new cartridge will stick out more than the very first cartridge (continue with step 3). Remember to put the clear base back to unlock the inhaler.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

a. Summary of the safety profile Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium bromide or to the ß2-adrenergic properties of olodaterol, the components of Spiolto Respimat b. e.
events attributed to Spiolto Respimat) observed in the tiotropium 5 microgram/olodaterol 5 microgram dose group (5646 patients), pooled from 8 active or placebo-controlled, parallel group clinical trials in COPD patients with treatment periods ranging between 4 and 52 weeks.
Adverse reactions reported in all clinical trials with Spiolto Respimat are shown below according to system organ class. These also include all adverse reactions previously reported with one of the individual components.
Frequency is defined using the following convention:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data) System Organ Class Adverse reaction Frequency Infections and infestations Nasopharyngitis not known Metabolism and nutrition disorders Dehydration not known Dizziness uncommon Insomnia rare Nervous system disorders Headache uncommon Vision blurred rare Glaucoma not known Eye disorders Intraocular pressure increased not known Atrial fibrillation rare Tachycardia uncommon Palpitations rare Cardiac disorders Supraventricular tachycardia rare Vascular disorders Hypertension rare Cough uncommon Dysphonia uncommon Laryngitis rare Pharyngitis rare Epistaxis rare Bronchospasm rare Respiratory, thoracic and mediastinal disorders Sinusitis not known Dry mouth uncommon Constipation rare Oropharyngeal candidiasis rare Gingivitis rare Nausea rare Intestinal obstruction Ileus paralytic not known Dysphagia not known Gastrooesophageal reflux disease not known Glossitis not known Stomatitis rare Gastrointestinal disorders Dental caries not known Hypersensitivity rare Angioedema rare Urticaria rare Pruritus rare Anaphylactic reaction not known Rash rare Skin infection and skin ulcer not known Skin and subcutaneous tissue disorders, Immune system disorders Dry skin not known Arthralgia rare Back pain1 rare Musculoskeletal and connective tissue disorders Joint swelling rare Urinary retention rare Urinary tract infection rare Renal and urinary disorders Dysuria rare 1 undesirable effects reported with Spiolto Respimat, but not with the individual components c.
Description of selected adverse reactions Spiolto Respimat combines anticholinergic and ß2-adrenergic properties due to its components tiotropium and olodaterol. 7% and 1% in the tiotropium 5 microgram and olodaterol 5 microgram arms, respectively.
04%) treated with Spiolto Respimat. Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation, intestinal obstruction including ileus paralytic and urinary retention. ß-adrenergic adverse reaction profile Olodaterol, one component of Spiolto Respimat is a member of the therapeutic class of long- acting beta2-adrenergic agonists.
Therefore the occurrence of other undesirable effects related to the beta-adrenergic agonist class, which are not listed above, should be taken into consideration, such as, arrhythmia, myocardial ischaemia, angina pectoris, hypotension, tremor, nervousness, muscle spasms, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis.
d. Other special populations An increase in anticholinergic effect may occur with increasing age. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

Asthma Striverdi Respimat should not be used in asthma. The long-term efficacy and safety of olodaterol in asthma have not been studied. e. as rescue therapy. Hypersensitivity As with all medications, immediate hypersensitivity reactions may occur after administration of Striverdi Respimat.
Paradoxical bronchospasm As with other inhaled medicines Striverdi Respimat may result in paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs Striverdi Respimat should be discontinued immediately and alternative therapy substituted.
g. 44 s), and in patients who are unusually responsive to sympathomimetic amines. Patients with a history of myocardial infarction during the previous year, unstable or life-threatening cardiac arrhythmia, hospitalized for heart failure during the previous year or with a diagnosis of paroxysmal tachycardia (>100 beats per minute) were excluded from the clinical trials.
Therefore the experience in these patient groups is limited. Striverdi Respimat should be used with caution in these patient groups. Cardiovascular effects Like other beta2-adrenergic agonists, olodaterol may produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.
In case such effects occur, treatment may need to be discontinued. In addition, beta-adrenergic agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave and ST segment depression, although the clinical significance of these observations is unknown.
Hypokalaemia Beta2-adrenergic agonists may produce significant hypokalaemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation.
5), which may increase the susceptibility to cardiac arrhythmias. Hyperglycaemia Inhalation of high doses of beta2-adrenergic agonists may produce increases in plasma glucose. Anaesthesia Caution needs to be taken in case of a planned operation with halogenated hydrocarbon anaesthetics due to an increased susceptibility to the adverse cardiac effects of beta agonist bronchodilators.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drug interactions

Drugs in the same class

Sources & citations